<DOC>
	<DOCNO>NCT01663935</DOCNO>
	<brief_summary>The purpose study evaluate document physiologic functional change visual performance retinal function patient diagnose albinism ( dopamine deficiency state ) follow trial oral Levodopa/carbidopa treatment .</brief_summary>
	<brief_title>Vision Response Dopamine Replacement</brief_title>
	<detailed_description>In study investigator propose retina albinism deficient dopamine , vision improvement occur result improve retinal function response deficient neurotransmitter dopamine . This study pretest-posttest design order determine improvement vision response replacement deficiency ( dopamine ) . The ERG test OCT critical determinant confirm vision improvement result improve retinal function , primary outcome data . Main outcome measure collect pre-treatment , 1 month , 3 month , 4 month . Change visual acuity measure logMAR Snellen SVEP 3 month treatment primary outcome . Patients include OCA1a patient , OCA1b , OCA2 , unclassified OCA . OCA1a patient clinically know bad vision , physiologically low ( absent ) level tyrosinase function ( Dopamine Production ) . All patient treat Levodopa/carbidopa 4mg/kg/day three divide dos .</detailed_description>
	<mesh_term>Albinism</mesh_term>
	<mesh_term>Albinism , Oculocutaneous</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>clinical diagnosis oculocutaneous albinism age 3 weight 25 lb . ocular albinism ocular pathology albinism neurologic disease , history myocardial infarction , history clinical depression , pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>levodopa</keyword>
	<keyword>Albinism</keyword>
	<keyword>dopamine</keyword>
	<keyword>oculocutaneous albinism</keyword>
	<keyword>vision</keyword>
	<keyword>retina function</keyword>
</DOC>